<DOC>
	<DOCNO>NCT03006029</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ( MTD ) recommend Phase 2 dose TAB08 administer intravenously ( i.v . ) patient advance solid malignancy .</brief_summary>
	<brief_title>Dose Escalation Study TAB08 Patients With Advanced Solid Neoplasms</brief_title>
	<detailed_description>This open-label , multi-center , sequential group , dose escalation study TAB08 patient metastatic unresectable advanced solid malignancy . The study consist 2 part : dose-escalation part standard `` 3+3 '' design , follow dose-expansion part maximum tolerate dose ( MTD ) determine . Patients must document recurrent refractory solid tumor ; patient enrol dose-expansion part trial must least one lesion may qualify target lesion base RECIST 1.1 criterion . Following provision sign informed consent , patient screen entry study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>1 . Subjects authorized representative must able provide write informed consent . 2 . Subjects must histological cytological evidence solid neoplasm standard therapy fail exist available patient due reason . 3 . Subjects enrolled expansion cohort must least one measurable evaluable lesion . 4 . Subjects must ECOG ( Eastern Cooperation Oncology Group ) performance status 0 1 . 5 . Subjects must ≥ 18 year age . 6 . Subjects must adequate organ function , define follow criterion : Absolute neutrophil count ( ANC ) &gt; 1,500/µL . Platelet count &gt; 75,000/µL . Hemoglobin ( Hb ) &gt; 8.0 g/dL . Serum creatinine &lt; 1.5 x upper limit normal ( ULN ) calculate Glomerular Filtration Rate &gt; 40 mL/min/1.73m2 . Serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 3 x ULN ( &lt; 5 x ULN subject know liver metastasis ) . 7 . At least 2 week least 5 halflives must elapse since prior treatment chemotherapy , target therapy , radiotherapy , immunotherapy , investigational anticancer therapy prior study drug administration . The maximum washout period exceed 4 week . . 8 . Subjects must recover effect prior surgery , radiotherapy , localize therapy , systemic therapy Grade 1 low ( except alopecia anemia Grade 2 permit ) . 9 . Subjects life expectancy ≥ 3 month study entry . 10 . Women childbearing potential men partner childbearing potential must agree abstain sexual intercourse use effective form contraception . 1 . Subjects uncontrolled concurrent illness , include , limited following : ongoing active infection require systemic treatment ; uncontrolled endocrine disease ; diabetes mellitus chronic obstructive pulmonary disease ( COPD ) require hospitalization within precede 6 month . 2 . Subjects uncontrolled arterial hypertension , heart failure New York Heart Association ( NYHA ) Class 3 4 , leave ventricular ejection fraction ( LVEF ) &lt; 50 % echocardiography , myocardial infarction , acute coronary syndrome and/or QT prolongation within precede 6 month history cerebrovascular accident include episode transient ischemic attack . 3 . Subjects alter mental status psychiatric illness social circumstance would limit compliance study requirement and/or obscure result . 4 . Immunocompromised subject , e.g. , subject know infected human immunodeficiency virus ( HIV ) medical history , subject active hepatitis A , B , C medical history . 5 . Subjects untreated symptomatic brain metastasis , subject leptomeningeal disease . ( Subjects treat metastasis , corticosteroid neurologically stable least 2 month may participate trial . ) 6 . A history major surgery within 28 day prior first dose study drug . 7 . Subjects history malignancy within precede 5 year ( except subject nonmelanoma skin cancer , cervical intraepithelial neoplasia , prostate cancer Gleason ≤ 6 Prostate Specific Antigen ( PSA ) &lt; 10 ng/mL , radically excise lobular breast carcinoma situ ductal breast carcinoma situ ≤ 15 mm ) unless undergone potentially curative therapy evidence disease 3 year ( ie , 5 year since diagnosis , treatment symptom disease last 3 year ) . 8 . Women pregnant nursing . 9 . Subjects disease , metabolic dysfunction , physical examination finding , clinical laboratory finding , opinion investigator , contraindicate use investigational drug , may render subject excessively high risk treatment complication . 10 . Subjects condition determine medical history , include substance abuse , opinion investigator , would render subject unable cooperate trial place subject undue risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>